Kineticos Ventures’ portfolio of investments is made up of biotechs and life science services companies striving to disrupt how drugs are developed, diseases are diagnosed, and patients are treated. The Kineticos Ventures fund focuses on significant, unmet medical needs in oncology, neurosciences, and rare diseases. In addition to targeting these disease states with patients in need, we look for companies utilizing disruptive technologies such as cell and gene therapy, gene editing, and mRNA/RNAi, all technologies dramatically changing how medicine is practiced.